journal article·2024-03-27Open access

One-Pot Microfluidics to Engineer Chitosan Nanoparticles Conjugated with Antimicrobial Peptides Using “Photoclick” Chemistry: Validation Using the Gastric Bacterium Helicobacter pylori

Diana R. Fonseca, Pedro M. Alves, Estrela Neto, Beatriz Custódio, Sofia Guimarães, Duarte Moura, Francesca Annis, Marco Martins, Ana Gomes, Cátia Teixeira, Paula Gomes, Rúben F. Pereira, Paulo Freitas, Paula Parreira, M. Cristina L. Martins

ACS Applied Materials & Interfaces· Volume 16· Issue 12

Abstract

High Resolution Image Download MS PowerPoint Slide Surface bioconjugation of antimicrobial peptides (AMP) onto nanoparticles (AMP-NP) is a complex, multistep, and time-consuming task. Herein, a microfluidic system for the one-pot production of AMP-NP was developed. Norbornene-modified chitosan was used for NP production (NorChit-NP), and thiolated-AMP was grafted on their surface via thiol–norbornene “photoclick” chemistry over exposure of two parallel UV LEDs. The MSI-78A was the AMP selected due to its high activity against a high priority (level 2) antibiotic-resistant gastric pathogen: Helicobacter pylori (H. pylori) . AMP-NP (113 ± 43 nm; zeta potential 14.3 ± 7 mV) were stable in gastric settings without a cross-linker (up to 5 days in pH 1.2) and bactericidal against two highly pathogenic H. pylori strains (10 11 NP/mL with 96 μg/mL MSI-78A). Eradication was faster for H. pylori 26695 (30 min) than for H. pylori J99 (24 h), which was explained by the lower minimum bactericidal concentration of soluble MSI-78A for H. pylori 26695 (32 μg/mL) than for H. pylori J99 (128 μg/mL). AMP-NP was bactericidal by inducing H. pylori cell membrane alterations, intracellular reorganization, generation of extracellular vesicles, and leakage of cytoplasmic contents (transmission electron microscopy). Moreover, NP were not cytotoxic against two gastric cell lines (AGS and MKN74, ATCC) at bactericidal concentrations. Overall, the designed microfluidic setup is a greener, simpler, and faster approach than the conventional methods to obtain AMP-NP. This technology can be further explored for the bioconjugation of other thiolated-compounds.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Antimicrobial Peptides and Activities · Inhalation and Respiratory Drug Delivery · Antimicrobial agents and applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

i3S − Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Rua Alfredo Allen, 208, 4200-135 Porto, Portugal

Instituto Nacional de Engenharia Biomédica, Universidade do Porto, R. Alfredo Allen 208, 4200-135 Porto, Portugal

Faculdade de Engenharia, Departamento de Engenharia Metalúrgica e de Materiais, Universidade do Porto, R. Dr. Roberto Frias, 4200-465 Porto, Portugal

LAQV-REQUIMTE, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do Porto, Rua do Campo Alegre 685, 4169-007 Porto, Portugal

ICBAS−Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Rua de Jorge Viterbo Ferreira, 4050-313 Porto, Portugal

INL, International Iberian Nanotechnology Laboratory, Av. Mte. José Veiga s/n, 4715-330 Braga, Portugal

INESC-MN, INESC Microsystems and Nanotechnologies, Rua Alves Redol 9, 1000-029 Lisboa, Portugal

Funding

European Regional Development Fund · Horizon 2020 Framework Programme · Funda??o para a Ci?ncia e a Tecnologia

References (61)

Show source-provided references
1. 10.1016/S0140-6736(21)02724-010.1016/S0140-6736(21)02724-0 ↗
2. 10.1038/nrgastro.2017.5710.1038/nrgastro.2017.57 ↗
3. 10.1111/apt.1456110.1111/apt.14561 ↗
4. 10.1136/gutjnl-2022-32774510.1136/gutjnl-2022-327745 ↗
5. 10.1016/J.JCONREL.2022.05.05010.1016/J.JCONREL.2022.05.050 ↗
6. 10.1080/1040841x.2021.189572110.1080/1040841x.2021.1895721 ↗
7. 10.1016/j.apmt.2024.10212310.1016/j.apmt.2024.102123 ↗
8. 10.1016/j.ijbiomac.2022.10.26510.1016/j.ijbiomac.2022.10.265 ↗
9. 10.1080/09205063.2020.187032310.1080/09205063.2020.1870323 ↗
10. 10.1016/j.ijbiomac.2022.02.03910.1016/j.ijbiomac.2022.02.039 ↗
11. 10.3390/molecules2003397210.3390/molecules20033972 ↗
12. 10.1163/092050609X1246434513768510.1163/092050609X12464345137685 ↗
13. 10.1016/j.actbio.2020.06.03510.1016/j.actbio.2020.06.035 ↗
14. 10.1038/s41598-019-53918-410.1038/s41598-019-53918-4 ↗
15. 10.1111/hel.1255510.1111/hel.12555 ↗
16. 10.1016/j.actbio.2010.11.00510.1016/j.actbio.2010.11.005 ↗
17. 10.1021/acs.biochem.8b0005210.1021/acs.biochem.8b00052 ↗
18. 10.1098/rsfs.2017.003010.1098/rsfs.2017.0030 ↗
19. 10.1016/j.actbio.2021.09.06310.1016/j.actbio.2021.09.063 ↗
20. 10.1039/D2BM01127A10.1039/D2BM01127A ↗
21. 10.1021/acsapm.2c0056310.1021/acsapm.2c00563 ↗
22. 10.1088/1361-6439/ab8dd210.1088/1361-6439/ab8dd2 ↗
23. 10.1021/acs.molpharmaceut.8b0087410.1021/acs.molpharmaceut.8b00874 ↗
24. 10.1016/j.lfs.2020.11776810.1016/j.lfs.2020.117768 ↗
25. 10.1002/cnma.20200022910.1002/cnma.202000229 ↗
26. 10.1016/j.jddst.2020.10213410.1016/j.jddst.2020.102134 ↗
27. 10.3390/ijms2024621210.3390/ijms20246212 ↗
28. 10.1016/j.actbio.2017.11.01610.1016/j.actbio.2017.11.016 ↗
29. 10.1016/j.carbpol.2017.02.05010.1016/j.carbpol.2017.02.050 ↗
30. AccQ•Tag Ultra Derivatization Kit. https://www.waters.com/webassets/cms/support/docs/715001331.pdf (accessed April 22, 2023).
31. 10.1038/1649510.1038/16495 ↗
32. 10.1038/4148310.1038/41483 ↗
33. 10.1016/j.ejpb.2018.02.03010.1016/j.ejpb.2018.02.030 ↗
34. Biological Evaluation of Medical Devices Part 5, Tests for in Vitro Cytotoxicity, ISO 10993–5, 2009.
35. Biological Evaluation of Medical Devices, Part 12, Sample Preparation and Reference Materials, SO 10993–12, 2004.
36. 10.1016/J.IJPHARM.2022.12158210.1016/J.IJPHARM.2022.121582 ↗
37. 10.1021/acsabm.9b0021810.1021/acsabm.9b00218 ↗
38. 10.1021/acs.biomac.8b0069610.1021/acs.biomac.8b00696 ↗
39. 10.1021/acsabm.0c0062910.1021/acsabm.0c00629 ↗
40. 10.1016/j.mtadv.2022.10020510.1016/j.mtadv.2022.100205 ↗
41. 10.1016/j.taml.2017.06.00210.1016/j.taml.2017.06.002 ↗
42. 10.1002/mabi.20190014510.1002/mabi.201900145 ↗
43. 10.1021/bm500899r10.1021/bm500899r ↗
44. 10.1002/adhm.20170094410.1002/adhm.201700944 ↗
45. 10.1021/acsabm.0c0090810.1021/acsabm.0c00908 ↗
46. 10.1016/j.matpr.2020.10.29510.1016/j.matpr.2020.10.295 ↗
47. 10.1177/0883911522108573810.1177/08839115221085738 ↗
48. 10.1002/anie.20221724610.1002/anie.202217246 ↗
49. 10.1021/nn304760510.1021/nn3047605 ↗
50. 10.1515/epoly.2010.10.1.69510.1515/epoly.2010.10.1.695 ↗
51. 10.1016/j.actbio.2014.02.02810.1016/j.actbio.2014.02.028 ↗
52. ’Rehman I. · 2020
53. 10.1186/s12876-019-1062-510.1186/s12876-019-1062-5 ↗
54. 10.2147/IDR.S28763110.2147/IDR.S287631 ↗
55. 10.1016/j.mcpro.2022.10042110.1016/j.mcpro.2022.100421 ↗
56. 10.3390/ijms2214744910.3390/ijms22147449 ↗
57. 10.1021/ja045664d10.1021/ja045664d ↗
58. 10.1371/journal.pone.006065710.1371/journal.pone.0060657 ↗
59. 10.1016/j.peptides.2004.09.01210.1016/j.peptides.2004.09.012 ↗
60. 10.1529/biophysj.105.07389010.1529/biophysj.105.073890 ↗
61. 10.1021/acsami.0c0203410.1021/acsami.0c02034 ↗